4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Connect Biopharma Holdings Limited (CNTB) operates in the Biotechnology industry and is headquartered in San Diego, United States with about 64 employees. Its market capitalization is roughly $153 million. In the fiscal year ended 2025-12-31, CNTB reported $0M in revenue and ($56M) in net income.
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD).
Interactive charts & full statements → Open the CNTB valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $26M | $0M | $0M | — |
| Operating Income (EBIT) | ($58M) | ($22M) | ($69M) | ($116M) | — |
| Net Income | ($56M) | ($16M) | ($62M) | ($118M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($20M) | ($16M) | ($18M) | ($13M) | ($11M) |
| Net Income | ($19M) | ($15M) | ($17M) | ($13M) | ($10M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $56M | $101M | $127M | $174M | — |
| Total Liabilities | $14M | $9M | $26M | $16M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive CNTB viewer.
About TickerBase · Data methodology & sources